Overview

Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase 1b/2 study is to estimate the treatment effect of study drug measuring progression free survival.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Carboplatin
Pemetrexed
Trebananib